Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Xcyte Digital Corp. Signs Agreement to Purchase Assets of Webinar.net (click to learn more) Viva Gold Reports Multiple High-Grade Gold Hits at the Tonopah Gold Project (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Edesa Biotech Inc EDSA

Healthcare Biotechnology
Edesa Biotech, Inc. is a Canada-based clinical-stage biopharmaceutical company developing various ways to treat inflammatory and immune-related diseases. The Company’s advanced drug candidate is EB05 (paridiprubart), a monoclonal antibody developed for acute and chronic disease indications that involve dysregulated innate immune responses. It is evaluating EB05 in a Phase III study as a... see more

Recent & Breaking News (NDAQ:EDSA)

Edesa Biotech Reports Fiscal 2nd Quarter 2022 Results

Accesswire May 13, 2022

Edesa Biotech Reports Dermatitis Study Enrolling Faster than Expected

Accesswire April 28, 2022

Edesa Biotech Appoints Strategy Expert to Board of Directors

Accesswire March 29, 2022

Edesa Biotech Announces Closing of $10.0 Million Registered Direct Offering

Accesswire March 24, 2022

Edesa Biotech Announces $10.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Accesswire March 22, 2022

Edesa Biotech Reports Enrollment Milestone in Phase 3 ARDS Study

Accesswire February 17, 2022

Edesa Biotech Reports Fiscal 1st Quarter 2022 Results

Accesswire February 14, 2022

Edesa Biotech to Join Ontario Bioscience Panel Discussion

Accesswire January 26, 2022

Edesa Biotech Receives Canadian Approval to Test COVID-19 Drug as Rescue Therapy

Accesswire January 13, 2022

Edesa Biotech Reports Fiscal Year 2021 Results

Accesswire December 28, 2021

Edesa Biotech Marks Enrollment Milestone in Dermatitis Study

Accesswire December 1, 2021

Edesa Biotech Extends COVID-19 Clinical Study to Poland

Accesswire November 4, 2021

Edesa Biotech Reports Favorable Mortality Reductions in COVID-19 Study

Accesswire October 19, 2021

Edesa Biotech Announces Positive Phase 2 Data of Its Monoclonal Antibody in Hospitalized COVID-19 Patients

Accesswire September 20, 2021

Edesa Biotech to Present at the H.C. Wainwright Global Investment Conference

Accesswire September 9, 2021

Edesa Biotech Enrolls More Than 525 COVID-19 Patients Ahead of Schedule

Accesswire August 26, 2021

Edesa Biotech Reports Fiscal 3rd Quarter 2021 Financial Results

Accesswire August 13, 2021

Edesa Biotech Extends Dermatitis Study to Canada

Accesswire July 13, 2021

This Could Massively Disrupt the $24.35 Billion NSAID Market

Press Releases June 25, 2021

Edesa Biotech Team Expands Leadership Team with Key Manufacturing Appointment

Accesswire June 23, 2021